Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.05
-0.20 (-1.10%)
Aug 3, 2026, 4:00 PM EDT - Market closed
Avalo Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -84.74 | -78.26 | -35.13 | -31.54 | -41.66 | -84.38 |
Depreciation & Amortization | 0.23 | 0.34 | 0.17 | 0.16 | 0.17 | 1.66 |
Stock-Based Compensation | 13.96 | 13.62 | 5.85 | 3.48 | 7.55 | 8.17 |
Other Adjustments | 8.79 | 9 | -15.24 | 6.47 | 7.25 | 0.82 |
Change in Receivables | - | - | -0.48 | 1.78 | 2.88 | -0.41 |
Changes in Inventories | - | - | - | 0.02 | 0.02 | -0.04 |
Changes in Accounts Payable | -0.33 | -0.15 | -0.16 | -2.44 | -0.49 | 0.8 |
Changes in Accrued Expenses | 1.02 | 6.66 | -1.11 | -9.05 | -3.63 | 3.25 |
Changes in Unearned Revenue | - | - | - | -0.09 | 0.09 | - |
Changes in Other Operating Activities | -0.36 | -2.68 | -2.96 | 0.53 | 1.07 | -0.76 |
Operating Cash Flow | -59.69 | -51.46 | -49.06 | -30.68 | -26.75 | -70.89 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | - | - | -0.16 | -0.1 | -0.11 |
Sale of Property, Plant & Equipment | - | - | - | 0.03 | - | - |
Purchases of Investments | - | -113.72 | - | - | - | - |
Proceeds from Sale of Investments | 25.51 | 32 | - | - | - | - |
Other Investing Activities | - | - | 0.36 | - | - | - |
Investing Cash Flow | -56.22 | -81.72 | 0.36 | -0.13 | -0.1 | -0.11 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | - | - | - | - | 32.9 |
Long-Term Debt Repaid | - | - | - | -21.24 | - | - |
Net Long-Term Debt Issued (Repaid) | - | - | - | -21.24 | - | 32.9 |
Issuance of Common Stock | - | 15.56 | 185.07 | 46.29 | -14.7 | 73.86 |
Repurchase of Common Stock | -1.29 | -0.51 | - | - | - | - |
Net Common Stock Issued (Repurchased) | -1.29 | 15.05 | 185.07 | 46.29 | -14.7 | 73.86 |
Other Financing Activities | - | -0.46 | -9.22 | - | - | - |
Financing Cash Flow | 15.99 | 14.59 | 175.85 | 25.04 | -14.7 | 106.76 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | -99.92 | -118.59 | 127.15 | -5.77 | -41.55 | 35.76 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -59.69 | -51.46 | -49.06 | -30.84 | -26.85 | -71.01 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | - | -87216.90% | -11123.80% | -1602.81% | -148.72% | -1315.39% |
Free Cash Flow Per Share | -3.78 | -3.84 | -6.54 | -111.04 | -684.81 | - |
Levered Free Cash Flow | -84.18 | -74.07 | -39.19 | -63.81 | -44.53 | -46.68 |
Unlevered Free Cash Flow | -78.76 | -68.89 | -72.8 | -38.39 | -40.33 | -77.15 |